C4 Therapeutics, Inc. (NASDAQ:CCCC) Director Sells $517,494.94 in Stock

C4 Therapeutics, Inc. (NASDAQ:CCCC) Director Elena Prokupets sold 10,321 shares of the firm’s stock in a transaction that occurred on Tuesday, September 21st. The shares were sold at an average price of $50.14, for a total value of $517,494.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Elena Prokupets also recently made the following trade(s):

  • On Friday, September 17th, Elena Prokupets sold 10,840 shares of C4 Therapeutics stock. The shares were sold at an average price of $50.05, for a total value of $542,542.00.
  • On Wednesday, September 15th, Elena Prokupets sold 54,193 shares of C4 Therapeutics stock. The shares were sold at an average price of $48.82, for a total value of $2,645,702.26.
  • On Monday, September 13th, Elena Prokupets sold 6,660 shares of C4 Therapeutics stock. The shares were sold at an average price of $50.07, for a total value of $333,466.20.
  • On Friday, September 10th, Elena Prokupets sold 2,550 shares of C4 Therapeutics stock. The shares were sold at an average price of $50.00, for a total value of $127,500.00.
  • On Monday, August 2nd, Elena Prokupets sold 4,257 shares of C4 Therapeutics stock. The stock was sold at an average price of $45.01, for a total value of $191,607.57.
  • On Thursday, July 29th, Elena Prokupets sold 11,336 shares of C4 Therapeutics stock. The stock was sold at an average price of $45.00, for a total value of $510,120.00.

Shares of NASDAQ:CCCC opened at $50.50 on Friday. The company has a market cap of $2.45 billion and a P/E ratio of -8.66. The company has a quick ratio of 10.81, a current ratio of 10.81 and a debt-to-equity ratio of 0.02. C4 Therapeutics, Inc. has a 52 week low of $22.40 and a 52 week high of $51.21. The business has a fifty day simple moving average of $43.15 and a 200-day simple moving average of $39.12.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Tuesday, August 10th. The company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.08. The business had revenue of $9.78 million during the quarter, compared to the consensus estimate of $7.45 million. C4 Therapeutics had a negative return on equity of 43.32% and a negative net margin of 257.05%. Sell-side analysts expect that C4 Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in CCCC. Price T Rowe Associates Inc. MD grew its position in shares of C4 Therapeutics by 69.0% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,544,837 shares of the company’s stock valued at $134,137,000 after purchasing an additional 1,447,028 shares during the period. BlackRock Inc. grew its position in C4 Therapeutics by 120.4% during the second quarter. BlackRock Inc. now owns 2,632,424 shares of the company’s stock valued at $99,610,000 after acquiring an additional 1,437,932 shares during the period. ArrowMark Colorado Holdings LLC grew its position in C4 Therapeutics by 454.7% during the second quarter. ArrowMark Colorado Holdings LLC now owns 1,395,621 shares of the company’s stock valued at $52,810,000 after acquiring an additional 1,144,004 shares during the period. Wasatch Advisors Inc. purchased a new stake in C4 Therapeutics during the first quarter valued at about $40,135,000. Finally, Vanguard Group Inc. grew its position in C4 Therapeutics by 262.6% during the second quarter. Vanguard Group Inc. now owns 1,406,840 shares of the company’s stock valued at $53,234,000 after acquiring an additional 1,018,882 shares during the period. 65.94% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on CCCC shares. Brookline Capital Management reaffirmed a “buy” rating on shares of C4 Therapeutics in a report on Friday, June 25th. HC Wainwright initiated coverage on C4 Therapeutics in a report on Friday, June 4th. They issued a “buy” rating and a $63.00 price target for the company. Brookline Capital Acquisition initiated coverage on C4 Therapeutics in a report on Thursday, June 24th. They issued a “buy” rating and a $54.00 price target for the company. Finally, BMO Capital Markets boosted their price target on C4 Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a report on Tuesday, June 22nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $51.50.

About C4 Therapeutics

C4 Therapeutics, Inc, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

Read More: QQQ ETF

Insider Buying and Selling by Quarter for C4 Therapeutics (NASDAQ:CCCC)

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.